Raymond James Downgrades Third Harmonic Bio (THRD) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
Third Harmonic Bio (THRD) Announces Phase 1 Clinical Results for THB335, Provides Corporate Strategic Update
February 11, 2025 7:00 AM ESTThird Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results from its Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of THB335 in healthy volunteers. These data are expected to support the advancement of THB335 into a Phase 2 clinical trial in chronic spontaneous urticaria (CSU). The Company is initiating a strategic review process to run in parallel with Phase 2 readiness activities to identify opportunities to maximize shareholder value.
From a drug development... More
